Is Lixte Biotechnology Holdings Inc (LIXT) overvalued? · $121.0M cap
Lixte Biotechnology Holdings Inc (LIXT) is a biotechnology company listed on NASDAQ.
This page asks whether Lixte Biotechnology Holdings Inc (LIXT) looks expensive on cached numbers — not a short thesis.
No cached income statement for LIXT, so there is no earnings base to call rich or cheap.
LIXT currently screens at market cap $121.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LIXT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LIXT stock page for the full model, not this heading.
Not investment advice.